Home › Compare › SZLSF vs NOBL

SZLSF vs NOBL: Dividend Comparison 2026

SZLSF yields 39215.69% · NOBL yields 2.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SZLSF wins by $4.252735580217355e+22M in total portfolio value
10 years
SZLSF
SZLSF
● Live price
39215.69%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.252735580217355e+22M
Annual income
$42,315,093,309,418,040,000,000,000,000.00
Full SZLSF calculator →
NOBL
NOBL
● Live price
2.14%
Share price
$106.01
Annual div
$2.27
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.8K
Annual income
$246.19
Full NOBL calculator →

Portfolio growth — SZLSF vs NOBL

📍 SZLSF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSZLSFNOBL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SZLSF + NOBL cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
SZLSF pays
NOBL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SZLSF
Annual income on $10K today (after 15% tax)
$3,333,333.33/yr
After 10yr DRIP, annual income (after tax)
$35,967,829,313,005,333,000,000,000,000.00/yr
NOBL
Annual income on $10K today (after 15% tax)
$182.19/yr
After 10yr DRIP, annual income (after tax)
$209.26/yr
At 15% tax rate, SZLSF beats the other by $35,967,829,313,005,333,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SZLSF + NOBL for your $10,000?

SZLSF: 50%NOBL: 50%
100% NOBL50/50100% SZLSF
Portfolio after 10yr
$2.1263677901086776e+22M
Annual income
$21,157,546,654,709,020,000,000,000,000.00/yr
Blended yield
99.50%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SZLSF buys
0
NOBL buys
0
No recent congressional trades found for SZLSF or NOBL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSZLSFNOBL
Forward yield39215.69% ✓2.14%
Annual dividend / share$2.00$2.27 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$4.252735580217355e+22M$22.8K ✓
Annual income after 10y$42,315,093,309,418,040,000,000,000,000.00 ✓$246.19
Total dividends collected$4.251340866571809e+22M ✓$2.3K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: SZLSF vs NOBL ($10,000, DRIP)

YearSZLSF PortfolioSZLSF Income/yrNOBL PortfolioNOBL Income/yrGap
1← crossover$3,932,269$3,921,568.63$10,914$214.34+$3.92M → SZLSF
2$1,445,390,825$1,441,183,297.58$11,897$218.63+$1445.38M → SZLSF
3$496,629,048,205$495,082,480,022.34$12,952$222.72+$496629.04M → SZLSF
4$159,510,701,964,776$158,979,308,883,196.16$14,086$226.62+$159510701.95M → SZLSF
5$47,892,225,784,148,210$47,721,549,333,045,900.00$15,302$230.33+$47892225784.13M → SZLSF
6$13,442,027,069,357,296,000$13,390,782,387,768,257,000.00$16,607$233.85+$13442027069357.28M → SZLSF
7$3,526,928,149,355,307,700,000$3,512,545,180,391,095,400,000.00$18,007$237.18+$3526928149355307.50M → SZLSF
8$865,104,634,553,737,800,000,000$861,330,821,433,927,700,000,000.00$19,508$240.35+$865104634553737856.00M → SZLSF
9$198,376,161,453,751,100,000,000,000$197,450,499,494,778,630,000,000,000.00$21,116$243.35+$198376161453751107584.00M → SZLSF
10$42,527,355,802,173,560,000,000,000,000$42,315,093,309,418,040,000,000,000,000.00$22,841$246.19+$4.252735580217355e+22M → SZLSF

SZLSF vs NOBL: Complete Analysis 2026

SZLSF — Stock

StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in the United States and Canada. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood. The company's lead product is Aristotle, a multi-cancer panel test for simultaneously screening for various cancers from a single sample of blood with high sensitivity and specificity for each cancer. It also offers ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer; COVID polymerase chain reaction testing and blood test analysis; Prostate Health Index, a screening test for prostate cancer; and BreastSentry, a test to determine a woman's risk for developing breast cancer. The company was founded in 1998 and is headquartered in Richmond Hill, Canada.

Full SZLSF Calculator →

NOBL — ETF

The fund will invest at least 80% of its total assets in component securities of the index. The index contains a minimum of 40 stocks, which are equally weighted, and no single sector is allowed to comprise more than 30% of the index weight. It seeks to remain fully invested at all times in securities and/or financial instruments that, in combination, provide exposure to the returns of the index without regard to market conditions, trends or direction.

Full NOBL Calculator →
📬

Get this SZLSF vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SZLSF vs SCHDSZLSF vs JEPISZLSF vs OSZLSF vs KOSZLSF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.